Assessing response to treatment using imaging with PET/MRI in advanced renal cancer

Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI): The REMAP study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12114913

Enrollment

Registered

2016-11-16

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma Cancer Malignant neoplasm of kidney, except renal pelvis

Interventions

Participants with metastatic renal cell cancer will undergo FDG PET/MRI scans at baseline, 12 and 24 weeks following the start of their standard treatment and results compared to the routine clinical

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients (male or female > 18 years old) with metastatic renal cell carcinoma 2. Metastases with =1 measurable sites, =2cm, planned for targeted therapy 3. ECOG performance status 0-2

Exclusion criteria

Exclusion criteria: 1. Contraindications to contrast-enhanced MRI or CT or FDG PET including renal impairment eGFR 2 4. Previous radiotherapy

Design outcomes

Primary

Measure	Time frame
disease response or non-response measured by PET/MRI and CT at 12 and 24 weeks and clinical examination and CT at 36 weeks.	—

Secondary

Measure	Time frame
Time to progression will be measured by clinical examination and CT at standard three to six monthly follow up clinic visits.	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Jul 23, 2026